few years, newly developed drugs, including oxaliplatin; the taxanes; irinotecan; and oral fluoropyrimidines, such as S-1 and capecitabine, have been introduced into chemotherapy regimens [1, 2] . Combination chemotherapy with these new drugs has increased response rates to over 50%, but has not increased the median survival time to over 11 months, and the therapies are often related to a higher frequency of severe adverse events than older regimens, even though some of these events are acceptable [1, 2] . Thus, there is a need for diagnostic methods that allow the prediction of clinical outcome and enable the pretherapeutic discrimination of treatment effect.
Introduction
The significant survival benefit of 5-fluorouracil (5-FU)-based chemotherapy for metastatic gastric cancer compared with best supportive care has been reported [1, 2] . In Western countries, 5-FU combined with cisplatin, and 5-FU combined with cisplatin plus epirubicin shave been referred to as the standard chemotherapy for metastatic gastric cancer, with the median survival time ranging from 7.3 to 10.5 months [1] . In Japan, 5-FU monotherapy still remains the reference arm of clinical trials for metastatic gastric cancer [2] . During the past fluoro-β-alanine (F-β-Ala), via dihydrofluorouracil (FUH 2 ), by the first and rate-limiting enzyme, dihydropyrimidine dehydrogenase (DPD) [6] (Fig. 1) . 5-FU degradation occurs in all tissues, including tumor tissues, but is highest in the liver [7] . The main mode of action of 5-FU is considered to be through its active metabolite: 5-fluoro-uridine-5′-triphosphate (FUTP) or 5-fluoro-2′deoxyuridine-5′-monophosphate (FdUMP) [8] . FUTP can be incorporated into RNA, while FdUMP suppresses thymidylate synthase (TS), an essential DNA de-novo synthetic enzyme that catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) [8] [9] [10] . FdUMP and TS form covalent ternary complexes with 5,10-methylenetetrahydrofolate (5,10-CH 2 -FH 4 ), which subsequently inhibit DNA synthesis (Fig. 1) .
The anabolic conversion of 5-FU into nucleotides such as FUTP or FdUMP is essential for its action, as illustrated in Fig. 1 , where three pathways are shown. Pathway 1: conversion directly to 5-fluoro-uridine-5′-monophosphate (FUMP) by orotate phosphoribosyltransferase (OPRT) in the presence of 5-phosphoribosyl-1-pyrophosphate (PRPP); pathway 2: conversion indirectly to FUMP in a sequence of reactions with the conversion of 5-FU to 5-fluorouridine (FUR), catayized by uridine phosphorylase (UP) in the presence of ribose-1-phosphate (Rib-1-P); and pathway 3: conversion indirectly to FdUMP by 2′deoxy-5-fluorouridine (FUdR), catalyzed by thymidine phosphorylase (TP) in the presence of deoxyribose-1-phosphate (dRib-1-P) [11, 12] . The preferential use of the OPRT pathway (pathway 1) was revealed to correlate with a higher sensitivity to 5-FU in human cancer cell lines and human xenograft models [11, 12] .
Capecitabine is converted into 5′-deoxy-5-fluorocytidine (5′-dFCR) by carboxyl esterase (CE) in the liver, and is subsequently further converted into 5′-deoxy-5-fluoro-uridine (5′-dFUR) by cytidine deaminase (CD) [13] . Finally, 5-FU results from the bioconversion of 5′-dFUR by TP (Fig. 1) . Tegafur is converted into 5-FU mainly by cytochrome P450 (CYP450) enzymes ( Fig. 1 ) in the liver [13] . CYP2A6 is the main CYP450 enzyme involved in tegafur activation, but CYP1A2 and CYP2C8 also play a significant role.
The relative expression of these enzymes participating in the 5-FU metabolic pathway may be related to treatment efficacy and toxicity. Table 1 shows several factors that have been reported as predictors of response to fluoropyrimidine-based chemotherapy in metastatic gastric cancer, using clinical samples [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Some of these factors include apoptosis-related factors such as p53 and bcl-2, angiogenetic factor, vascular endothelial growth factor (VEGF), and nucleotide excision repair-related factors, such as ERCC1 and GADD45A, which are associated with the antitumor effect of cisplatin combined with 5-FU. However, the most extensively examined factors are several enzymes involved in the 5-FU metabolic pathway.
Thymidylate synthase (TS)
The relation between TS expression in metastatic tumors and outcome has been most clearly demonstrated in colorectal cancer, regardless of measurement methodologies such as enzyme activity, protein levels, and mRNA levels [28] . In the presence of a given concentration of FdUMP and 5,10-CH 2 -FH 4 , ternary complexes are more efficiently formed in tumors with low TS expression than in those with high TS expression, resulting in greater inhibition of DNA synthesis, followed by increased cytotoxicity [10] .
TS enzyme activity is assessed either by TS catalytic activity or by TS binding capacity for FdUMP [29] . Maehara et al. [30] indicated an association between TS binding activity and sensitivity to tegafur/uracil (UFT) and 5-FU in gastric cancer. Tsujinaka et al. [31] demonstrated that TS binding activity was inhibited more strongly by the continuous infusion of 5-FU than by the bolus administration of 5-FU. These assays not only provide an estimate of the absolute intracellular TS content but allow the measurement of the level of the functional enzyme, which is the true target of drug activity, and/or its affinity for the inhibitor FdUMP. Despite these theoretical advantages, major practical issues, such as need for large amounts of fresh tissues, and the unstable enzyme activity, have precluded the clinical application of these assays. More sensitive methods for quantitating the levels of TS protein, by immunohistochemistry [32, 33] or TS mRNA expression [34, 35] , were developed to allow investigations of the relation between TS levels and response to fluoropyrimidine in larger series of patients. Immunohistochemistry is widely used, and its cost is low, although it is not quantitative and not objective. In contrast, measurement of TS mRNA expression is very highly sensitive and is suitable for use with very small amounts of biopsy material although there is a lack of control of sample morphology and intratumoral heterogeneity.
In gastric cancer patients, Johnston et al. [36] reported, for the first time, that both the intratumoral TS mRNA level and TS protein expression were associated with the clinical outcome, in 12 patients who received 5-FU-based chemotherapy. This result was confirmed in other studies, including patients treated with 5-FU and cisplatin [14, 19] . Nonresponding tumors had significantly higher intratumoral TS gene expression levels than responding ones [14] . Additionally, patients with low TS gene expression in tumors survived for longer than those with high tumor TS gene expression [14, 19] . Boku et al. [15] reported that TS protein expression, evaluated by immunohistochemistry in primary tumors, could predict survival in patients treated with 5-FU and cisplatin for metastatic tumors. In the adjuvant setting, Ishikawa et al. [37] reported that high intratumoral TS mRNA levels in preoperative biopsy specimens were associated with poorer survival after surgery than low intratumoral TS mRNA levels in patients with stage III or IV gastric cancer.
Thus, many studies have shown that TS is a predictor of response to fluoropyrimidine treatment in gastric cancer, similar to colorectal cancer, but the predictive value remains controversial. As can be seen in Table 2 , the predictive values of TS expression may be affected by a wide range of factors, including the treatment setting (adjuvant, palliative for metastatic disease, or preoperative), as well as differences in chemotherapeutic regimens (5-FU alone versus 5-FU-based combination chemotherapy) and the type of oral fluoropyrimidine derivative used [14, 15, 18, 19, 22, 24, 26, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . Overall, most of the studies have found that TS expression is a prognostic marker of survival, independently of whether therapy is given in an adjuvant or metastatic setting. In the metastatic setting, however, TS expression is not necessarily a predictive marker of response. High levels of TS expression reflect tumor progression, [22] . We previously reported that high TS gene expression in primary gastric cancer was closely related to poor response in metastatic tumors, with shorter survival, when the patients were treated with S-1 alone. However, when irinotecan was combined with S-1, intratumoral TS gene expression had no predictive value in terms of response or survival [24] . The predictive power was overcome by irinotecan combination therapy with S-1 for metastatic gastric cancer. Further investigations are therefore necessary to define the predictive value of TS for clinical outcome according to specific treatment regimens.
Similar to studies of colorectal cancer, genetic polymorphisms of TS are becoming an increasingly important field in the study of gastric cancer. These polymorphisms include tandem repeat sequences (tandem repeats) and a single-nucleotide polymorphism (G > C) within the second repeat of the 3 repeat in the 5′-untranslated region (UTR) of the TS gene, as well as 6-bp insertions and deletions within the 3′-UTR [13] (Fig. 2) . As for the 5′-UTR, tumors with 2 repeat alleles or G > C mutations are reported to have low levels of TS expression, increasing their sensitivity to fluoropyrimidines [13] . However, the clinical significance of these polymorphisms remains unclear, because the frequency of 2 repeat alleles is lower in Japanese than in Caucasians [13, 43, [46] [47] [48] .
Dihydropyrimidine dehydrogenase (DPD)
DPD catalyzes the initial, rate-limiting step of the catabolism of 5-FU. Low levels of DPD have been shown to be associated with 5-FU-induced toxicity [7] . A route that has been extensively evaluated in relation to 5-FU resistance is the intratumoral degradation of 5-FU by DPD. In vivo studies using human cancer cell lines have demonstrated an inverse correlation between both DPD enzyme activity and DPD mRNA expression and 5-FU response [7] . Furthermore, in metastatic colorectal cancer, responding tumors had significantly lower levels of DPD gene expression than nonresponding ones, when treated with fluoropyrimidinebased chemotherapy [49, 50] .
Ishikawa et al. [51] were the first to evaluate the correlation between both DPD gene expression and DPD protein expression and 5-FU sensitivity in gastric cancer. Takabayashi et al. [52] reported that intratumoral DPD activity in resected specimens after neoadjuvant chemotherapy with low-dose cisplatin and 5-FU was lower in responders than in nonresponders. Napieralski et al. [18] reported that high intratumoral DPD gene expression was correlated with no response and an adverse outcome in gastric cancer patients treated with 5-FU and cisplatin. Terashima et al. [22] reported that high intratumoral DPD enzyme levels were associated with poorer survival after surgery than low intratumoral DPD enzyme levels in patients with resectable gastric cancer, when treated with fluoropyrimidine-based adjuvant chemotherapy. However, conflicting results were obtained from different studies, as shown in Table 3 [17, 18, [22] [23] [24] 26, 37, 44, [52] [53] [54] [55] [56] [57] . These results might be explained by variations in methodologies and treatment protocols, or by variations in respect to treatment setting (adjuvant, neoadjuvant, or palliative setting), as well as discrepancy in TS expression, as mentioned above. In addition, sampling errors, with contamination by stromal tissues, may contribute to the inconsistency of these results, because DPD expression was observed in stromal tissues as well as in cancerous tissues [58] . Further studies are necessary to establish the predictive and prognostic values of DPD expression in gastric cancer.
We examined the relation of intratumoral DPD gene expression to treatment response in patients with metastatic gastric cancer who received S-1 alone or S-1 combined with irinotecan [24] . The antitumor effect of S-1 in gastric cancer was not influenced by intratumoral DPD gene expression, regardless of whether S-1 was used alone, or in combination with irinotecan. This might be explained by the inhibition of intratumoral DPD by gimeracil, which is contained in S-1 as a DPD inhibitor [59] . There were no correlations between the antitumor activity of S-1 and DPD activity in human gastric xenografts [60] . Miyamoto et al. [26] reported that patients with tumors possessing positive DPD expression showed a slightly higher response rate and longer survival than those with negative DPD expression in tumors, although the difference was without statistical significance, when DPD expression was evaluated by immunohistochemistry using a recombinant human DPD polyclonal antibody. In 61 patients with gastric scirrhous carcinoma, the response rate was significantly higher in patients with DPD-positive tumors than in those with DPD-negative ones in an S-1 group, as compared with a 5-FU group [27] . S-1 is thought to have antitumor activity even in tumors with high levels of DPD expression which are essentially resistant to 5-FU.
We also demonstrated that TS and DPD gene expressions in gastric cancer tissue differed according to the histological differentiation; the TS gene was more highly expressed in differentiated adenocarcinomas, while the DPD gene was more highly expressed in undifferentiated ones [58] . In a phase II study of S-1 for metastatic gastric cancer, the response rate of undifferentiated type was higher than that for differentiated type [61] . The higher response rate of S-1 for the undifferentiated type may be explained, at least in part, by both low TS expression and the inhibition of high DPD expression by gimeracil.
Thymidine phosphorylase (TP)
Increased TP activity in various cancer cell lines and human xenograft models results in an increase in sensitivity to 5-FU [62] . However, in the clinical setting, a high baseline level of TP gene expression in colorectal tumors was associated with nonresponse to fluoropyrimidine therapy [49, 63, 64] . Tumors with high TP expression levels were associated with poorer tumor shrinkage and shorter survival in 61 gastric cancer patients who received neoadjuvant chemotherapy with 5-FU and cisplatin [18] . TP expression levels were negatively correlated with an antitumor effect of S-1 treatment in metastatic gastric cancer [25] . Pathway 3 (phosphorylation of 5-FU to FdUMP via FUdR; (Fig. 1)) is not important for the anabolism of 5-FU because of the lack of TP cofactor dRib-1-P at physiological concentrations [65] . Conversely, high TP concentrations, in conjunction with the normally low dRib-1-P levels, drive the reaction in the opposite direction [66] . Apart from the function of TP in 5-FU phosphorylation, TP (which is identical to platelet-derived endothelial cell growth factor) has been shown to play an important role in angiogenesis, cancer invasiveness, metastasis, and antiapoptotic effects [62] . These data support the findings that TP expression is a negative predictor of treatment with 5-FU or S-1 in gastric cancer.
5′-dFUR and capecitabine are metabolized to 5-FU by intratumoral TP [13] (Fig. 1) . Experimental studies have shown that tumors with high TP expression are more sensitive to 5′-dFUR and capecitabine [11] . When treated with 5′-dFUR-based combination chemotherapy, patients with TP-positive tumors responded to the treatment, whereas those with TP-negative tumors did not respond [20] . 5-FU converted from 5′-dFUR and capecitabine by intratumoral TP to 5-FU is degraded by DPD. Therefore, the TP/DPD ratio shows a significant correlation with sensitivity to 5′-dFUR and capecitabine [22, 67] . Nishina et al. [23] showed that the intratumoral TP/DPD ratio was higher among responders than nonresponders in patients with metastatic gastric cancer who received 5′-dFUR-based combination chemotherapy.
The available evidence thus suggests that different metabolizing enzymes influence the response to different fluoropyrimidine derivatives. For instance, S-1 is thought to be effective against tumors with high DPD expression, whereas 5′-dFUR and capecitabine are most effective against tumors with high TP expression (Fig. 3) .
Orotate phosphoribosyltransferase (OPRT)
Phosphorylation is necessary to activate 5-FU into its nucleotides. In humans, the preferential use of the OPRT pathway (pathway 1; Fig. 1 ) was revealed to correlate with a higher sensitivity to 5-FU in cancer cell lines and human xenograft models [11, 12] . Higher levels of OPRT expression were associated with greater sensitivity to 5-FU [68, 69] . We previously showed, in the treatment of patients with metastatic colorectal cancer using UFT combined with leucovorin, that patients with high tumor OPRT gene expression had a better response rate and longer survival than those with low tumor OPRT gene expression [64] . In metastatic gastric cancer, tumors with high OPRT expression showed a better response to S-1 alone than those with low OPRT expression, consistent with previously reported results [25] . These findings suggest that phosphorylation may be an extremely important determinant of sensitivity to fluoropyrimidines.
"Polygenic" approach
Each of the enzymes involved in the 5-FU metabolic pathway discussed above could be useful for predicting the clinical outcome of 5-FU-based chemotherapy. However, the genes for these enzymes involved in the 5-FU pathway do not act in isolation. The expression of more than a single gene, such as a combination of TS, DPD, and TP, or a combination of DPD and OPRT, has been reported to permit the identification of a high percentage of colorectal cancer patients responding to treatment [49, 50, 64] . We evaluated whether the response to S-1 treatment could be predicted in terms of the expression of five genes involved in the 5-FU metabolic pathway (TS, DPD, OPRT, TP, and UP) Fig. 3 . Detoxification and activation of 5-FU and 5-FU analogues (S-1, 5′-dFUR, and capecitabine). 5-FU is detoxified by dihydropyrimidine dehydrogenase (DPD) into α-fluoro-β-alanine (FBAL). Gimeracil, contained in S-1, reversibly inhibits intratumoral DPD activity. 5-FU is activated mainly by the orotate phosphoribosyltransferase (OPRT) pathway, while 5′-dFUR and capecitabine are converted by thymidine phosphorylase (TP) into 5-FU [25] . The combined evaluation of two genes, OPRT and TS for response, and TS and TP for survival, had higher predictive value than the expression of a single gene. Combined evaluation of the expression of genes involved in the 5-FU metabolic pathway appears to be a promising approach in gastric cancer, as well as in colorectal cancer.
This current review has focused on only TS, DPD, TP, and OPRT, although there are over 29 genes involved in the 5-FU metabolic pathway [3] . As 5-FU mimics uracil, 5-FU is catabolized and anabolized by the same biological pathway as that for the naturally occurring pyrimidines. Not surprisingly, these 5-FU pathway genes correlate with one other. Kidd et al. [70] reported that multiple correlations among 5-FU pathway genes differentiated at least three groups of genes and two groups of patients according to the hierarchical clustering of 24 5-FU pathway genes in the colorectal cancer tissues of 52 patients. The next step will be the "polygenic" approach including all 29 5-FU pathway genes in patients with metastatic gastric cancer treated with fluoropyrimidines. Additionally, DNA microarraybased gene expression profiling may provide novel insights into the biology of drug resistance, as well as providing a more precise tool to identify patients predisposed to treatment failure [5] .
Limitations in predicting clinical outcome, and future perspectives
Finally, we would like to point out two limitations in the clinical application of 5-FU pathway gene expression to predict clinical outcome. The first limitation is a methodological issue; how to measure and what tissues are to be measured. Protein expression is measured by immunohistochemistry or enzyme-linked immunosorbent assay (ELISA), and RNA levels are quantified by reverse-transcriptase-polymerase chain reaction (RT-PCR) or real-time RT-PCR, which is quantitatively superior to immunohistochemistry [29] . Each of these techniques has its advantages and disadvantages, with some of these mentioned above. Heterogeneity within tumor tissues and the contamination of normal tissue in tumor samples are critical problems. These problems could be partly solved by using laser capture microdissection from paraffin-embedded sections, in combination with real-time RT-PCR [58] . In addition, tumor tissue is commonly used to evaluate determinants to predict response. Because chemotherapy for metastatic gastrointestinal cancer is targeted to the metastatic lesions, the expression of determinants for tumor response should be measured in the metastatic tissues. However, a considerable number of patients with advanced disease will have metastases that are usually inaccessible for biopsy, whereas the primary cancer may provide an ample source of tissue for marker analysis as a surrogate. Therefore, further studies are necessary to establish the optimal and standardized methods to collect samples and evaluate determinants.
The second limitation is related to the lack of wellcontrolled prospective clinical trials with adequate sample size and statistical power to demonstrate the values to predict clinical outcome. In colorectal cancer, the clinical significance of TS expression as a predictor of response to fluoropyrimidines is considered as "evidence level I" [71] . Nevertheless, Bertino et al. [72] have questioned whether the measurement of TS expression is "ready for prime time?". In clinical practice, TS expression is still not used to predict response to colorectal cancer treatment. This is because the value of the measurement of TS expression to predict response has not been validated by large prospective clinical studies.
Conclusions
In this post-genomic era, a growing body of evidence suggests that the expression of enzymes involved in the 5-FU metabolic pathway may have important implications for drug efficacy. The remaining challenge is the comprehensive identification of these determinants to predict clinical outcome in patients receiving fluoropyrymidine treatment, and the assessment of the usefulness of these determinants, alone as well as in combination. Combination chemotherapy with fluoropyrimidine agents and other drugs, such as cisplatin, irinotecan, and the taxanes, is now gaining wider acceptance in clinical practice. In this circumstance, the identification of predictive markers for clinical outcome is being facilitated by the advent of DNA microarray-based gene expression profiling. Conversely, deep insights into the 5-FU pathway may be helpful for selecting the genes that are truly meaningful for the prediction of clinical outcome from the results obtained by DNA microarray, in patients receiving 5-FU-based combination chemotherapy.
Again, randomized prospective translational treatment trials are needed to confirm previously reported associations that were drawn from limited retrospective studies. Considering the narrow therapeutic index for anticancer agents, the ability to better predict both the response and any potentially life-threatening toxic effects is highly important for clinicians. The prediction of adverse events, combined with the prediction of antitumor effect, may lead to the "tailoring" of chemotherapy in metastatic gastric cancer in the near future.
